
    
      This is a multi-center, expanded access, open label study of carfilzomib for patients with
      relapsed and refractory multiple myeloma. The study is designed to provide access to patients
      with relapsed and refractory disease that have received at least 4 prior regimens and are not
      eligible for any other enrolling carfilzomib Onyx-sponsored studies enrolling patients in the
      United States.
    
  